- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00983697
FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer (ACRIN6685)
A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18-PET/CT scan, may help doctors find head and neck cancer and find out how far the disease has spread. It may also help doctors plan the best treatment.
PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing the tumor and planning neck surgery in patients with newly diagnosed head and neck cancer.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
OBJECTIVES:
Primary
- Determine the negative predictive value of PET/CT imaging based upon pathologic sampling of the neck lymph nodes in patients with head and neck cancer planning to undergo N0 neck surgery.
- Determine the potential of PET/CT imaging to change treatment.
Secondary
- Estimate the sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinical N0 neck (both by neck and lymph node regions) or other local sites.
- Determine the effect of other factors (e.g., tumor size, location, secondary primary tumors, or intensity of FDG uptake) that can lead to identification of subsets of patients that could potentially forego neck dissection or that can provide preliminary data for subsequent studies.
- Compare the cost-effectiveness of using PET/CT imaging for staging head and neck cancer vs current good clinical practices.
- Evaluate the incidence of occult distant body metastasis discovered by whole-body PET/CT imaging.
- Correlate PET/CT imaging findings with CT/MRI findings and biomarker results.
- Evaluate the quality of life of these patients, particularly of those patients whose management could have been altered by imaging results.
- Evaluate PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction.
- Compare baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence, disease-free survival, and overall survival.
- Determine the proportion of neck dissections that are extended (i.e., additional levels that clinicians intend to dissect beyond the initial surgery plan) based on local-reader PET/CT imaging findings shared with the surgeon before dissection.
- Estimate the optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging.
- Evaluate the impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location).
OUTLINE: This is a multicenter study.
Patients undergo fludeoxyglucose F 18-PET/CT imaging. Approximately 14 days later, patients undergo unilateral or bilateral neck dissection.
Patients complete quality-of-life questionnaires at baseline and at 1, 12, and 24 months after surgery.
Patients undergo blood and tissue sample collection periodically for biomarker analysis.
Patients are followed up periodically for up to 2 years after surgery.
Тип исследования
Регистрация (Ожидаемый)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Beijing, Китай, 100730
- Peking Union Medical College Hospital
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90089-9181
- USC/Norris Comprehensive Cancer Center and Hospital
-
-
Florida
-
Safety Harbor, Florida, Соединенные Штаты, 34695
- Morton Plant Mease Cancer Care at Mease Countryside Hospital
-
Tampa, Florida, Соединенные Штаты, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40245
- Jewish Hospital Heart and Lung Institute
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Соединенные Штаты, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
-
-
North Carolina
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest University Comprehensive Cancer Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19104-4283
- Abramson Cancer Center of the University of Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
DISEASE CHARACTERISTICS:
Histologically confirmed newly diagnosed squamous cell carcinoma (SCC) of the head and neck , including any of the following sites:
- Oral cavity
- Oropharynx, including base of tongue and tonsils
- Larynx
- Supraglottis
Stage T2-T4, N0-N3 disease
Unilateral or bilateral neck dissection planned
- No N2c disease (if bilateral disease is present)
Has ≥ 1 clinically N0 neck side as defined by clinical exam (physical exam with CT scan and/or MRI)
- A N0 neck must be planned to be dissected for the patient to be eligible
- . The N0 neck can be either ipsilateral to the head and neck tumor or the contralateral N0 neck if a bilateral neck dissection is planned
CT scan and/or MRI taken within the past 4 weeks to confirm SCC of the head and neck
- Simultaneous diagnostic CT with PET scan allowed; however, PET cannot be used as part of the criteria to define the N0 neck disease
- For CT scan and/or MR images from other institutions, ACRIN recommends a re-read by a local neuro-radiologist to ensure compliance
- No sinonasal cancer, salivary gland cancer, thyroid cancer, nasopharyngeal cancer, or advanced skin cancer
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Negative pregnancy test
- Weight ≤ 350 lbs
- No poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications (optimally, patients will have glucose < 150 mg/dL)
- No underlying medical condition that would preclude surgery (neck dissection)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Диагностика
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: FDG PET/CT
Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Negative predictive value of PET/CT imaging for staging the N0 neck based upon pathologic sampling of the neck lymph nodes
Временное ограничение: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True negative cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Sensitivity and diagnostic yield of PET/CT imaging for detecting occult metastasis in the clinically N0 neck (both by neck and lymph node regions) or other local sites
Временное ограничение: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True positive cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
The diagnostic yield is defined as the ratio of cancers to total screened
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Determine which factors (e.g., tumor size, secondary primary tumors, location, or intensity of FDG uptake) may identify patients who can forego neck dissection
Временное ограничение: Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
True positive cases will be determined by histopathology reports.
The test will be defined as positive when SUVmax value of ≥ 2.0; and negative otherwise.
The diagnostic yield is defined as the ratio of cancers to total screened
|
Within Two Weeks Before Surgery and after sampling of neck lymph nodes
|
Cost-effectiveness and cost-benefit of using PET/CT imaging for staging of head and neck cancer vs current good clinical practices
Временное ограничение: 2 years post-surgery
|
The outcome measure will use the total cost of care for each participant to compute the incremental cost-effectiveness ratio (ICER)
|
2 years post-surgery
|
Incidence of occult distant body metastasis discovered by whole body PET/CT imaging
Временное ограничение: Within Two Weeks Before Surgery
|
this outcome will count the distant body metastasis not previously seen and report the results as a percentage.
|
Within Two Weeks Before Surgery
|
Correlation of PET/CT imaging findings with CT/MRI findings and biomarker results
Временное ограничение: Within Two Weeks Before Surgery
|
the outcome measure will consist of paired proportions of dichotomized PET/CT and CT/MRI test results; and biomarker test results
|
Within Two Weeks Before Surgery
|
Quality of life (QOL), particularly in patients whose management could have been altered by imaging results
Временное ограничение: 2 years post-surgery
|
QOL will be assessed using SF-36, Non-Utility HUI, and UW-QoL scores
|
2 years post-surgery
|
Evaluation of the PET/CT imaging and biomarker data for complementary contributions to metastatic disease prediction
Временное ограничение: Within Two Weeks Before Surgery
|
the metastatic disease status is the response variable and PET/CT test results and biomarker data are predictors.
|
Within Two Weeks Before Surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of recurrence
Временное ограничение: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to recurrence
|
2 years post-surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of disease-free survival
Временное ограничение: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to disease-free survival
|
2 years post-surgery
|
Comparison of baseline PET/CT imaging and biomarker data with 2-year follow up as an adjunct assessment of their prediction of overall survival
Временное ограничение: 2 years post-surgery
|
model the associations of PET/CT test results and biomarker data (predictors) to overall survival (censored responses)
|
2 years post-surgery
|
Proportion of neck dissections that are extended based on local-reader PET/CT imaging findings shared with the surgeon before dissection
Временное ограничение: Within Two Weeks Before Surgery
|
Outcome is defined as the number patients who surgeons intend to dissect levels beyond the initial surgery plan
|
Within Two Weeks Before Surgery
|
Optimum cutoff value of standardized uptake values for diagnostic accuracy of PET/CT imaging
Временное ограничение: Within Two Weeks Before Surgery
|
ROC analysis will be used to maximize the youden index and estimate the optimum cutoff value of SUV for diagnostic accuracy of PET/CT on N0 neck
|
Within Two Weeks Before Surgery
|
Impact of PET/CT imaging on the N0 neck across different tumor subsites (defined by anatomic location)
Временное ограничение: Within Two Weeks Before Surgery
|
Diagnostic Accuracy measures will be calculated using ROC analysis, subset by anatomic location
|
Within Two Weeks Before Surgery
|
Соавторы и исследователи
Соавторы
Следователи
- Учебный стул: Val J. Lowe, MD, Mayo Clinic
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- плоскоклеточный рак губы и полости рта III стадии
- веррукозная карцинома полости рта III стадия
- плоскоклеточный рак губы и полости рта IV стадии
- Веррукозная карцинома полости рта IV стадии
- плоскоклеточный рак ротоглотки III стадия
- IV стадия плоскоклеточного рака ротоглотки
- плоскоклеточный рак гортани III стадии
- плоскоклеточный рак гортани IV стадии
- Плоскоклеточный рак губы и полости рта II стадии
- Плоскоклеточный рак гортани II стадии
- Плоскоклеточный рак ротоглотки II стадии
- рак языка
- Веррукозная карцинома полости рта II стадии
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CDR0000654703
- U01CA080098 (Грант/контракт NIH США)
- U01CA079778 (Грант/контракт NIH США)
- ACRIN-6685 (Другой идентификатор: CIP ID)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
See ACRIN data sharing policy:
https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx
Сроки обмена IPD
Критерии совместного доступа к IPD
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования терапевтическая традиционная хирургия
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteРекрутингОстеоартрит, тазобедренный суставСоединенное Королевство
-
University Hospital Inselspital, BerneЗавершенныйРандомизированное контролируемое исследование | Желудочковый перитонеальный шунт | Осложнения шунта | Отказ шунтаШвейцария
-
Cognoa, Inc.ПрекращеноРасстройство аутистического спектраСоединенные Штаты
-
Dr. Faruk SemizЗапись по приглашению
-
MidAtlantic RetinaAlcon ResearchЗавершенныйСравнение 3D-визуализации и микроскопа для VR-хирургииСоединенные Штаты
-
University of TriesteЗавершенныйРак молочной железыИталия
-
National Cancer Centre, SingaporeЗавершенныйЗаболевания щитовидной железыСингапур
-
Ethicon Endo-SurgeryПрекращеноОжирениеСоединенные Штаты, Германия
-
St. Joseph's Healthcare HamiltonHamilton Academic Health Sciences OrganizationЗавершенныйРак легкого, немелкоклеточныйКанада
-
Seoul National University HospitalJohnson & Johnson Medical CompaniesЗавершенныйРак желудкаКорея, Республика